Hepatitis B: The case for combination therapy

Current Opinion in Investigational Drugs

Volumn 10, Issue 8, 2009, Pages 795-803

  Bowden, Scott ^a   Shaw, Tim ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

Antiviral resistance; Antiviral therapy; Chronic HBV infection; Combination therapy; RT inhibitor

Indexed keywords

ABACAVIR; ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; AMDOXOVIR; CARBOVIR; CLEVUDINE; DEOXYGUANOSINE DERIVATIVE; DIOXOLANE GUANINE; EMTRICITABINE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; LAMIVUDINE; PEGINTERFERON ALPHA; PRODRUG; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROPYLFUMARATE; UNCLASSIFIED DRUG;

ADD ON THERAPY; AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CHRONIC HEPATITIS; CLINICAL TRIAL; CROSS RESISTANCE; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; MITOCHONDRIAL TOXICITY; MIXED INFECTION; MONOTHERAPY; NONHUMAN; POPULATION SIZE; REVIEW; SEROCONVERSION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS MUTATION; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON ALFA-2A; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 68649114323     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Zetterstrom R: Nobel Prize to Baruch Blumberg for the discovery of the aetiology of hepatitis B. Acta Paediatr (2008) 97(3): 384-387.
2. Lavanchy D: Chronic viral hepatitis as a public health issue in the world. Best Pract Res Clin Gastroenterol (2008) 22(6):991- 1008.
3. Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A: A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): A final report. Hepatology (1981) 1(5):377-385.
4. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR: Human hepatitis B vaccine from recombinant yeast. Nature (1984) 307 (5947):178-180.
5. Chen DS: Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B. J Hepatol (2009) 50(4):805-816.
6. Zuckerman JN: Review: Hepatitis B immune globulin for prevention of hepatitis B infection. J Med Virol (2007) 79(7): 919-921.
7. Gambarin-Gelwan M: Hepatitis B in pregnancy. Clin Liver Dis (2007) 11(4):945-963.
8. Oliveri F, Santantonio T, Bellati G, Colombatto P, Mels GC, Carriero L, Dastoli G, Pastore G, Ideo G, Bonino F, Brunetto MR: Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. Am J Gastroenterol (1999) 94(5):1366-1372.
9. Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G: Side effects of interferon-α therapy. Pharm World Sci (2005) 27(6):423-431.
10. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, Chutaputti A, Chang WY, Zahm FE, Pluck N: PEGinterferon α-2a (40 kDa): An advance in the treatment of hepatitis B e antigenpositive chronic hepatitis B. J Viral Hepat (2003) 10(4):298-305. • Describes the benefits of PEG-IFN treatment over treatment with conventional IFN.
11. Chen RY, Bowden S, Desmond PV, Dean J, Locarnini SA: Effects of interferon α therapy on the catalytic domains of the polymerase gene and basal core promoter, precore and core regions of hepatitis B virus. J Gastroenterol Hepatol (2003) 18(6):630-637.
12. Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, Luo KX, Paik SW, Liaw YF, Button P, Popescu M: HBeAg and hepatitis B virus DNA as outcome predictors during therapy with PEGinterferon α-2a for HBeAg-positive chronic hepatitis B. Hepatology (2008) 47(2):428-434.
13. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, Dauvergne A, Asselah T, Boyer N, Bedossa P, Valla D et al: Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon α-2a in HBeAgnegative patients. Hepatology (2009) 49(4):1151-1157.
14. Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E et al: Hepatitis B virus surface antigen levels: A guide to sustained response to PEGinterferon α-2a in HBeAg-negative chronic hepatitis B. Hepatology (2009) 49(4):1141-1150.
15. Shaw T, Locarnini SA: Hepatic purine and pyrimidine metabolism: Implications for antiviral chemotherapy of viral hepatitis. Liver (1995) 15(4):169-184.
16. Nassal M: Hepatitis B viruses: Reverse transcription a different way. Virus Res (2008) 134 (1-2) :235-249.
17. Shaw T, Bartholomeusz A, Locarnini S: HBV drug resistance: Mechanisms, detection and interpretation. J Hepatol (2006) 44(3):593-606.
18. Seok JI, Lee DK, Lee CH, Park MS, Kim SY, Kim HS, Jo HY, Kim DS: Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology (2009) 49(6):2080-2086.
19. Pharmasset voluntarily halts clinical studies with clevudine in hepatitis B infected patients: Pharmasset Inc, Princeton, NJ, USA (2009). investor.pharmasset.com/releasedetail.cfm?releaseID=378789
20. Cihlar T, Delaney WE, Mackman R: Tenofovir and adefovir as antiviral agents. In: Modified Nucleosides in Biochemistry, Biotechnology and Medicine. Herdewijn P (Ed), Wiley-VCH, Weinheim, Germany (2008):601-630.
21. 173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol (2003) 77(21):11833-11841.
22. Berdis AJ: DNA polymerases as therapeutic targets. Biochemistry (2008) 47(32):8253-8260.
23. Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, Opolon P, Katlama C, Poynard T: Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology (1999) 30(5):1302-1306.
24. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, Tzakis AG, Schiff ER, Brown NA: Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet (1997) 349 (9044):20-22.
25. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology (1998) 27(6):1670-1677. •• The first comprehensive report to describe lamivudine resistance.
26. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF: Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology (2001) 33(3):751-757.
27. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A et al: Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology (2003) 125(2):292-297. • The first report of adefovir resistance.
28. Nakanishi H, Kurosaki M, Asahina Y, Onuki Y, Ueda K, Nishimura Y, Tsuchiya K, Kitamura T, Uchihara M, Miyake S, Enomoto N et al: Polymerase domain B mutation is associated with hepatitis relapse during long-term lamivudine therapy for chronic hepatitis B. Intervirology (2005) 48(6):381-388.
29. Pai SB, Bozdayi AM, Pai RB, Beker T, Sarioglu M, Turkyilmaz AR, Grier J, Yurdaydin C, Schinazi RF: Emergence of a novel mutation in the FLLA region of hepatitis B virus during lamivudine therapy. Antimicrob Agents Chemother (2005) 49(7):2618-2624.
30. No authors listed: NIH consensus development statement on management of hepatitis B. NIH Consens State Sci Statements (2008) 25(2):1-29.
31. Hadziyannis SJ, Vassilopoulos D: Telbivudine in the treatment of chronic hepatitis B. Expert Rev Gastroenterol Hepatol (2008) 2(1):13-22.
32. Gish RG, Trinh H, Leung N, Chan FK, Fried MW, Wright TL, Wang C, Anderson J, Mondou E, Snow A, Sorbel J et al: Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: A two-year study. J Hepatol (2005) 43(1):60-66.
33. Yuen MF, Lai CL: Adefovir dipivoxil in chronic hepatitis B infection. Expert Opin Pharmacother (2004) 5(11):2361-2367.
34. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Arterburn S et al: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med (2005) 352(26):2673-2681.
35. Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S, Borroto-Esoda K, Frederick D, Rousseau F: Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2008) 48(3):750-758.
36. Fung SK, Andreone P, Han SH, Rajender Reddy K, Regev A, Keeffe EB, Hussain M, Cursaro C, Richtmyer P, Marrero JA, Lok AS: Adefovirresistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol (2005) 43(6):937-943.
37. Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL, Gibbs CS, Parvaz P, Werle B, Trépo C, Zoulim F: Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol (2003) 39(6):1085-1089.
38. Dai CY, Chuang WL, Hsieh MY, Lee LP, Huang JF, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Tsai JF et al: Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B. Antiviral Res (2007) 75(2):146-151.
39. Kwon HC, Cheong JY, Cho SW, Choi JM, Hong SP, Kim SO, Yoo WD: Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy. J Gastroenterol Hepatol (2009) 24(1): 49-54.
40. Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, Chung YH, Lee YS, Yoo W, Kim SO: Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology (2006) 43(6):1385-1391. •• Describes how resistance to one NRTI can unexpectedly compromise the efflcacy of another NRTI, even if the NRTIs belong to different structural categories.
41. Yeh CT, Chien RN, Chu CM, Liaw YF: Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology (2000) 31(6):1318-1326.
42. 172 mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology (2008) 48(1):88-98.
43. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M et al: Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med (2008) 359(23):2442-2455.
44. Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS: Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol (2008) 48(3):391-398.
45. Lacombe K, Gozlan J, Boyd A, Boelle P Y, Bonnard P, Molina JM, Miailhes P, Lascoux-Combe C, Serfaty L, Zoulim F, Girard PM: Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients. Antivir Ther (2008) 13(5):705- 713.
46. De Clercq E, Field HJ: Antiviral Chemistry & Chemotherapy's Current Antiviral Agents FactFile (2nd edition): Retroviruses and Hepadnaviruses. Antivir Chem Chemother (2008) 19(2):75-105.
47. Sheldon J, Camino N, Rodes B, Bartholomeusz A, Kuiper M, Tacke F, Nunez M, Mauss S, Lutz T, Klausen G, Locarnini S, Soriano V: Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther (2005) 10(6):727-734.
48. 194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology (2008) 49(4):1158-1165.
49. Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, Fang J, Yu CF, Zhang S, Mazzucco CE, Eggers B et al: Two-year assessment of entecavir resistance in lamivudinerefractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother (2007) 51(3):902-911.
50. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P, Ayres A et al: Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother (2004) 48(9):3498-3507. •• Describes how entecavir resistance can occur following the development of resistance to lamivudine.
51. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ: Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology (2009) 49(5):1503-1514.
52. Shaw T, Bowden S, Locarnini S: Rescue therapy for drug resistant hepatitis B: Another argument for combination chemotherapy? Gastroenterology (2004) 126(1):343-347.
53. Kumar M, Sarin SK: Systematic review: Combination therapies for treatment-naïve chronic hepatitis B. Aliment Pharmacol Ther (2008) 27(12):1187-1209. •• A comprehensive review of clinical trials that used various combination therapies.
54. Rudin D, Shah SM, Kiss A, Wetz RV, Sottile VM: Interferon and lamivudine vs. interferon for hepatitis B e antigen-positive hepatitis B treatment: Meta-analysis of randomized controlled trials. Liver Int (2007) 27(9):1185-1193.
55. Rudin D: Lamivudine and interferon versus lamivudine monotherapy for HBeAg-positive hepatitis B treatment: A meta-analysis of randomized, controlled trials. Adv Ther (2007) 24(4):784-795.
56. Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, Chan FK, Hung LC, Lee YT, Tam JS, Lam CW et al: A randomized, controlled trial of combination therapy for chronic hepatitis B: Comparing pegylated interferon-α2b and lamivudine with lamivudine alone. Ann Intern Med (2005) 142(4):240-250.
57. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY et al: PEGinterferon α-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med (2005) 352(26):2682-2695.
58. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, Han S, Poynard T, Myers M, Chao G, Lloyd D et al: A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology (2005) 129(2):528-536.
59. Sung JJ, Lai JY, Zeuzem S, Chow WC, Heathcote EJ, Perrillo RP, Brosgart CL, Woessner MA, Scott SA, Gray DF, Gardner SD: Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol (2008) 48(5):728-735. • One of the few descriptions of the results of combination NRTI therapy.
60. Hui CK, Zhang HY, Bowden S, Locarnini S, Luk JM, Leung KW, Yueng YH, Wong A, Rousseau F, Yuen KY, Naoumov NN et al: 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol (2008) 48(5):714-720. • Another major description of combined NRTI therapy.
61. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM: Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology (1999) 30(2):567-572.